

# A randomised controlled trial of racemic epinephrine versus salbutamol for treatment of respiratory distress in bronchiolitis

<b>Submission date</b> 19/04/2005	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 20/04/2005	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 15/02/2008	<b>Condition category</b> Respiratory	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Joanne Langley

**Contact details**  
5850 University Avenue  
Halifax, Nova Scotia  
Canada  
B3K 6R8

## Additional identifiers

**Protocol serial number**  
N/A

## Study information

**Scientific Title**

**Study objectives**

Aerosolised racemic epinephrine given to hospitalised children under two years of age with bronchiolitis is more effective than aerosolised salbutamol in relieving respiratory distress.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

The protocol was approved by the Ethics Review Board at both participating institutions.

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Bronchiolitis

**Interventions**

Racemic epinephrine or salbutamol.

**Intervention Type**

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Racemic epinephrine

**Primary outcome(s)**

Wheezing and retractions measured by the Respiratory Distress Assessment Instrument each day during hospitalisation.

**Key secondary outcome(s)**

1. Length of stay
2. RSV antigen detection test
3. Feeding pattern
4. Adverse events
5. Parental report of feeding and respiratory status one week after discharge

**Completion date**

31/12/2002

**Eligibility**

**Key inclusion criteria**

Children less than two years of age with first episode wheezing.

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Child

**Upper age limit**

2 years

**Sex**

All

**Key exclusion criteria**

Children were not eligible for enrollment if they:

1. Had a previous diagnosis of asthma
2. Were critically ill
3. Had chronic pulmonary or cardiac disease

Other exclusion criteria included:

4. Allergy to sodium metabisulfite
5. Presence of tachycardia exceeding 200 beats per minute
6. Use of glucocorticoids
7. Sympathomimetic amines or monoamine oxidase inhibitor therapy

**Date of first enrolment**

01/01/1999

**Date of final enrolment**

31/12/2002

**Locations****Countries of recruitment**

Canada

**Study participating centre**

5850 University Avenue

Halifax, Nova Scotia

Canada

B3K 6R8

# Sponsor information

## Organisation

Lung Association of Nova Scotia (Canada)

## Funder(s)

### Funder type

Research organisation

### Funder Name

Lung Association of Nova Scotia (Canada)

### Funder Name

IWK Health Center Research Office (Canada)

## Results and Publications

### Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	Results	05/05/2005		Yes	No